DE602004028367D1 - Neue indolderivate als faktor xa-inhibitoren - Google Patents

Neue indolderivate als faktor xa-inhibitoren

Info

Publication number
DE602004028367D1
DE602004028367D1 DE602004028367T DE602004028367T DE602004028367D1 DE 602004028367 D1 DE602004028367 D1 DE 602004028367D1 DE 602004028367 T DE602004028367 T DE 602004028367T DE 602004028367 T DE602004028367 T DE 602004028367T DE 602004028367 D1 DE602004028367 D1 DE 602004028367D1
Authority
DE
Germany
Prior art keywords
factor
compounds
formula
inhibitors
factor viia
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE602004028367T
Other languages
English (en)
Inventor
Marc Nazare
Volkmar Wehner
Kurt Ritter
Volker Laux
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanofi Aventis Deutschland GmbH
Original Assignee
Sanofi Aventis Deutschland GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Aventis Deutschland GmbH filed Critical Sanofi Aventis Deutschland GmbH
Publication of DE602004028367D1 publication Critical patent/DE602004028367D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Obesity (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Indole Compounds (AREA)
DE602004028367T 2003-05-19 2004-05-05 Neue indolderivate als faktor xa-inhibitoren Expired - Lifetime DE602004028367D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP03011306A EP1479677A1 (de) 2003-05-19 2003-05-19 Neue Indolderivate als Faktor Xa-Inhibitoren
PCT/EP2004/004751 WO2004101554A1 (en) 2003-05-19 2004-05-05 New indole derivatives as factor xa inhibitors

Publications (1)

Publication Number Publication Date
DE602004028367D1 true DE602004028367D1 (de) 2010-09-09

Family

ID=33040953

Family Applications (1)

Application Number Title Priority Date Filing Date
DE602004028367T Expired - Lifetime DE602004028367D1 (de) 2003-05-19 2004-05-05 Neue indolderivate als faktor xa-inhibitoren

Country Status (15)

Country Link
US (1) US7196103B2 (de)
EP (2) EP1479677A1 (de)
JP (1) JP4676960B2 (de)
AT (1) ATE475659T1 (de)
AU (1) AU2004238495B2 (de)
BR (1) BRPI0410466A (de)
CA (1) CA2526066A1 (de)
CL (1) CL2004001074A1 (de)
DE (1) DE602004028367D1 (de)
MX (1) MXPA05012232A (de)
PA (1) PA8603601A1 (de)
PE (1) PE20050156A1 (de)
TW (1) TW200510393A (de)
UY (1) UY28325A1 (de)
WO (1) WO2004101554A1 (de)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1314733A1 (de) * 2001-11-22 2003-05-28 Aventis Pharma Deutschland GmbH Indol-2-carbonsäureamide als Faktor-Xa-Hemmer
US7358268B2 (en) * 2002-12-04 2008-04-15 Sanofi-Aventis Deutschland Gmbh Imidazole derivatives as factor Xa inhibitors
US7429581B2 (en) 2002-12-23 2008-09-30 Sanofi-Aventis Deutschland Gmbh Pyrazole-derivatives as factor Xa inhibitors
US7317027B2 (en) * 2003-05-19 2008-01-08 Sanofi-Aventis Deutschland Gmbh Azaindole-derivatives as factor Xa inhibitors
US7223780B2 (en) * 2003-05-19 2007-05-29 Sanofi-Aventis Deutschland Gmbh Triazole-derivatives as blood clotting enzyme factor Xa inhibitors
EP1479675A1 (de) * 2003-05-19 2004-11-24 Aventis Pharma Deutschland GmbH Indazolderivate als Faktor Xa-Inhibitoren
EP1479677A1 (de) 2003-05-19 2004-11-24 Aventis Pharma Deutschland GmbH Neue Indolderivate als Faktor Xa-Inhibitoren
US7741341B2 (en) 2003-05-19 2010-06-22 Sanofi-Aventis Deutschland Gmbh Benzimidazole-derivatives as factor Xa inhibitors
EP1571154A1 (de) * 2004-03-03 2005-09-07 Aventis Pharma Deutschland GmbH Derivate des Beta-Alanins als Hemmer des Faktors Xa
FR2888847B1 (fr) 2005-07-22 2007-08-31 Sanofi Aventis Sa Derives de n-(heteriaryl)-1-heteorarylalkyl-1h-indole-2- carboxamides, leur preparation et application en therapeutique
US7977359B2 (en) 2005-11-04 2011-07-12 Amira Pharmaceuticals, Inc. 5-lipdxygenase-activating protein (FLAP) inhibitors
GB2431927B (en) 2005-11-04 2010-03-17 Amira Pharmaceuticals Inc 5-Lipoxygenase-activating protein (FLAP) inhibitors
ES2593047T3 (es) 2006-02-03 2016-12-05 Opko Renal, Llc Tratamiento de la insuficiencia y deficiencia de vitamina D con 25-hidroxivitamina D2 y 25-hidroxivitamina D3
CA2655499C (en) 2006-06-21 2015-10-27 Proventiv Therapeutics, Llc Method of treating and preventing secondary hyperparathyroidism_with vitamin d repletion and vitamin d replacemnt therapies
EP3335712A1 (de) 2007-04-25 2018-06-20 Opko Renal, LLC Verfahren zur sicheren und effektiven behandlung und vorbeugung von sekundärem hyperparathyroidismus bei chronischer nierenerkrankung
HUE063590T2 (hu) 2007-04-25 2024-01-28 Eirgen Pharma Ltd Szabályozott felszabadulású 25-hidroxi-D-vitamin
TW200920369A (en) 2007-10-26 2009-05-16 Amira Pharmaceuticals Inc 5-lipoxygenase activating protein (flap) inhibitor
AU2009204048B2 (en) 2008-01-11 2013-08-01 Albany Molecular Research, Inc. (1-azinone) -substituted pyridoindoles as MCH antagonists
US8962239B2 (en) 2008-04-02 2015-02-24 Opko Renal, Llc Methods useful for vitamin D deficiency and related disorders
CN102137858B (zh) 2008-05-23 2014-07-23 潘米拉制药有限责任公司 5-脂氧合酶-活化蛋白抑制剂
AU2010241567B2 (en) 2009-04-29 2013-10-31 Amarin Pharmaceuticals Ireland Limited Pharmaceutical compositions comprising EPA and a cardiovascular agent and methods of using the same
WO2011003007A1 (en) * 2009-07-01 2011-01-06 Albany Molecular Research, Inc. Azabicycloalkane-indole and azabicycloalkane-pyrrolo-pyridine mch-1 antagonists, methods of making, and use thereof
EP2448585B1 (de) * 2009-07-01 2014-01-01 Albany Molecular Research, Inc. Azinon-substituiertes azepin[b]indol und pyrido-pyrrolo-azepin mch-1 antagonisten, verfahren zur herstellung und verwendung davon
US8618299B2 (en) * 2009-07-01 2013-12-31 Albany Molecular Research, Inc. Azinone-substituted azapolycycle MCH-1 antagonists, methods of making, and use thereof
US9073925B2 (en) * 2009-07-01 2015-07-07 Albany Molecular Research, Inc. Azinone-substituted azabicycloalkane-indole and azabicycloalkane-pyrrolo-pyridine MCH-1 antagonists, methods of making, and use thereof
CA2797537C (en) 2010-03-29 2021-11-23 Cytochroma Inc. Use of 25-hydroxyvitamin d compound for reducing parathyroid levels
US8993765B2 (en) 2010-12-21 2015-03-31 Albany Molecular Research, Inc. Tetrahydro-azacarboline MCH-1 antagonists, methods of making, and uses thereof
WO2012088038A2 (en) 2010-12-21 2012-06-28 Albany Molecular Research, Inc. Piperazinone-substituted tetrahydro-carboline mch-1 antagonists, methods of making, and uses thereof
KR101847947B1 (ko) 2013-03-15 2018-05-28 옵코 아이피 홀딩스 Ⅱ 인코포레이티드 안정화되고 변형된 비타민 ｄ 방출 제형
KR20170047265A (ko) 2014-08-07 2017-05-04 옵코 아일랜드 글로벌 홀딩스 리미티드 25-하이드록시비타민 d를 이용한 보조요법
KR20230056790A (ko) 2016-03-28 2023-04-27 옵코 아일랜드 글로벌 홀딩스 리미티드 비타민 d 치료 방법

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11469A (en) * 1854-08-08 boynton
US4675332A (en) * 1984-12-10 1987-06-23 Warner-Lambert Company Acidic tetrazolyl substituted indole compounds and their use as antiallergy agents
JPH0287282A (ja) * 1988-09-22 1990-03-28 Nec Corp グラフ作図レイアウト決定方式
US5506134A (en) 1990-10-22 1996-04-09 Corvas International, Inc. Hypridoma and monoclonal antibody which inhibits blood coagulation tissue factor/factor VIIa complex
US5833982A (en) 1991-02-28 1998-11-10 Zymogenetics, Inc. Modified factor VII
US5788965A (en) 1991-02-28 1998-08-04 Novo Nordisk A/S Modified factor VII
TW229140B (de) * 1992-06-05 1994-09-01 Shell Internat Res Schappej B V
WO1995029189A1 (en) 1994-04-26 1995-11-02 Selectide Corporation FACTOR Xa INHIBITORS
FR2763337B1 (fr) * 1997-05-13 1999-08-20 Sanofi Sa Nouveaux derives du triazole, un procede pour leur preparation et compositions pharmaceutiques les contenant
US20040043995A1 (en) 1997-05-13 2004-03-04 Eric Bignon Novel triazole derivatives, process for their preparation and pharmaceutical compositions containing them
AU743881B2 (en) * 1997-12-24 2002-02-07 Sanofi-Aventis Deutschland Gmbh Indole derivatives as inhibitors or factor Xa
CA2338727A1 (en) * 1998-08-03 2000-02-17 Edward David Mihelich Indole spla2 inhibitors
EP0987274A1 (de) 1998-09-15 2000-03-22 Hoechst Marion Roussel Deutschland GmbH Faktor VIIa Inhibitore
US6486211B1 (en) * 1999-10-22 2002-11-26 Smithkline Beecham Corporation Indole compounds
US7053070B2 (en) * 2000-01-25 2006-05-30 Warner-Lambert Company Pyrido[2,3-d]pyrimidine-2,7-diamine kinase inhibitors
US6436965B1 (en) * 2000-03-02 2002-08-20 Merck Frosst Canada & Co. PDE IV inhibiting amides, compositions and methods of treatment
MXPA02011609A (es) * 2000-05-26 2003-03-27 Nippon Shinyaku Co Ltd Compuestos heterociclicos.
US7030123B2 (en) * 2000-05-31 2006-04-18 Astrazeneca Ab Indole derivatives with vascular damaging activity
US20030165837A1 (en) 2000-06-14 2003-09-04 The Scripps Research Institute Method for screening DNA binding
AU2001269885A1 (en) * 2000-06-14 2001-12-24 The Scripps Research Institute Distamycin a analogs
US6525202B2 (en) * 2000-07-17 2003-02-25 Wyeth Cyclic amine phenyl beta-3 adrenergic receptor agonists
EP1217000A1 (de) 2000-12-23 2002-06-26 Aventis Pharma Deutschland GmbH Faktor Xa und Faktor VIIa Inhibitoren
DE10147672A1 (de) * 2001-09-27 2003-04-10 Bayer Ag Substituierte 2,5-Diamidoindole und ihre Verwendung
US7064135B2 (en) * 2001-10-12 2006-06-20 Novo Nordisk Inc. Substituted piperidines
EP1314733A1 (de) * 2001-11-22 2003-05-28 Aventis Pharma Deutschland GmbH Indol-2-carbonsäureamide als Faktor-Xa-Hemmer
US7358268B2 (en) 2002-12-04 2008-04-15 Sanofi-Aventis Deutschland Gmbh Imidazole derivatives as factor Xa inhibitors
US7429581B2 (en) 2002-12-23 2008-09-30 Sanofi-Aventis Deutschland Gmbh Pyrazole-derivatives as factor Xa inhibitors
US7078419B2 (en) * 2003-03-10 2006-07-18 Boehringer Ingelheim Pharmaceuticals, Inc. Cytokine inhibitors
US7049323B2 (en) * 2003-04-25 2006-05-23 Bristol-Myers Squibb Company Amidoheterocycles as modulators of the melanocortin-4 receptor
US7741341B2 (en) 2003-05-19 2010-06-22 Sanofi-Aventis Deutschland Gmbh Benzimidazole-derivatives as factor Xa inhibitors
EP1479677A1 (de) 2003-05-19 2004-11-24 Aventis Pharma Deutschland GmbH Neue Indolderivate als Faktor Xa-Inhibitoren
EP1479675A1 (de) 2003-05-19 2004-11-24 Aventis Pharma Deutschland GmbH Indazolderivate als Faktor Xa-Inhibitoren
US7223780B2 (en) 2003-05-19 2007-05-29 Sanofi-Aventis Deutschland Gmbh Triazole-derivatives as blood clotting enzyme factor Xa inhibitors
US7405670B2 (en) * 2005-07-29 2008-07-29 Fitzgerald Timothy W Method and system for detecting and isolating stray voltage

Also Published As

Publication number Publication date
PA8603601A1 (es) 2004-11-26
US20050033049A1 (en) 2005-02-10
EP1633746A1 (de) 2006-03-15
JP4676960B2 (ja) 2011-04-27
EP1479677A1 (de) 2004-11-24
US7196103B2 (en) 2007-03-27
JP2006528940A (ja) 2006-12-28
MXPA05012232A (es) 2006-08-18
AU2004238495A1 (en) 2004-11-25
BRPI0410466A (pt) 2006-05-30
WO2004101554A1 (en) 2004-11-25
AU2004238495B2 (en) 2010-07-22
PE20050156A1 (es) 2005-04-27
ATE475659T1 (de) 2010-08-15
UY28325A1 (es) 2004-12-31
EP1633746B1 (de) 2010-07-28
CL2004001074A1 (es) 2005-03-28
TW200510393A (en) 2005-03-16
CA2526066A1 (en) 2004-11-25

Similar Documents

Publication Publication Date Title
DE602004028367D1 (de) Neue indolderivate als faktor xa-inhibitoren
DE602004020761D1 (de) INDAZOLDERIVATE ALS FAKTOR Xa-INHIBITOREN
DE60110263D1 (de) Oxybenzamidderivate als faktor-xa-inhibitoren
WO2003044014A8 (en) Indole-2-carboxamides as factor xa inhibitors
TW200505914A (en) Pyrazole-derivatives as factor Xa inhibitors
IL171843A (en) TRIAZOLE DERIVATIVES AS FACTOR Xa INHIBITORS
NO20025810D0 (no) Faktor VIIA-inhibitoriske (tio)ureaderivater, deres fremstilling og anvendelse
DK1423357T3 (da) Urinstofderivater med antiproteolytisk aktivitet
TNSN05297A1 (en) BENZIMIDAZOLE-DERIVATIVES AS FACTOR Xa INHIBITORS
YU29702A (sh) N-gvanidinoalkilamidi, njihovo dobijanje, njihova primena i farmaceutski preparati koji ih obuhvataju
TNSN05296A1 (en) AZAINDOLE-DERIVATIVES AS FACTOR Xa INHIBITORS
TW200504027A (en) Imidazole-derivatives as factor Xa inhibitors
TW200716620A (en) Heteroaryl-carboxylic acid (sulfamoyl alkyl) amide-derivatives as factor Xa inhibitors
JO2467B1 (en) New indole derivatives as an inhibitor of Xa